Few & Far Between: Conversations from the Front Lines of Drug Development
Episodes
Episode 66: Mark Abelson, Founder of Ora Clinical
16 Dec 2025
Contributed by Lukas
Are clinical trial protocols a true art form? Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes gues...
Video Episode 65 - Amit Etkin, Founder and CEO of Alto Neuroscience
24 Nov 2025
Contributed by Lukas
With biotech, is it the destination, the journey, or both? Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien ...
Video Episode 64 - Professor Justin Stebbing
11 Nov 2025
Contributed by Lukas
Will GLP-1's one day replace our morning coffee? Find out in a special video episode of the Few & Far Between podcast! Host Chris O'Brien welcomes...
Video Episode 63 - Bruce Leuchter, MD, President and CEO of Neurvati Neurosciences
28 Oct 2025
Contributed by Lukas
What if the future of biotech is actually late-stage execution? Welcome to our first video episode of the Biorasi Few & Far Between podcast with y...
Episode 62: Ken Suzuki, Chief Marketing Officer at Nautilus Biotechnology
22 Oct 2025
Contributed by Lukas
When is the right time for a biotech to bring in a Chief Marketing Officer/CMO? Find out in our latest episode of the Biorasi Few & Far Between po...
Episode 61: Woody Bryan, President and CEO of Revolo Biotherapeutics
01 Oct 2025
Contributed by Lukas
Why is a feather-light touch important in fighting infections? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris...
Episode 60: Part Two: Yochi Slonim, Co-Founder and CEO at Anima Biotech
17 Sep 2025
Contributed by Lukas
Can AI see and talk to human cells? Find out in today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim...
Episode 59, Part One: Yochi Slonim, Co-Founder and CEO at Anima Biotech
03 Sep 2025
Contributed by Lukas
What do software bugs and human cells have in common? Find out in today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien wel...
Episode 58: Jerry McLaughlin, CEO and Board Member at Life Biosciences
14 Aug 2025
Contributed by Lukas
How does a biopharma background prepare you for the biotech playground? Find out in our latest episode of the Biorasi Few & Far Between podcast! H...
Episode 57: Jim Brown, DVM, President and CEO of DURECT Corporation
22 Jul 2025
Contributed by Lukas
Is the epigenome the "software" of the cell nucleus? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien w...
Episode 56, Part Two: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics
15 Jul 2025
Contributed by Lukas
How do experienced troubleshooters solve a difficult problem? By asking the right questions first! Welcome back to part two of our conversation with ...
Episode 55: Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®
09 Jul 2025
Contributed by Lukas
How much do you know about clinical trials in Latin America? Take a deep dive with us as we explore the benefits and risks of running studies in this ...
Episode 54, Part One: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics
28 May 2025
Contributed by Lukas
The challenge? Decoding the human immune system. Get ready to meet the top challenger on today's episode of the Biorasi Few & Far Between podcast....
Episode 53: Frank David, Founder and Managing Director, Pharmagellan
29 Apr 2025
Contributed by Lukas
How do mission, vision, and data analysis fit into today's biotech goals? Host Chris O'Brien welcomes Frank David, Founder and Managing Director of Ph...
Episode 52: Joshua Kresh, Emily Michiko Morris, and Mark Schultz, IPPI
23 Apr 2025
Contributed by Lukas
How does a biotech balance great science with IP security to tell their story? Find out on today's episode of the Few & Far Between podcast! Host ...
Episode 51: Dan Oliver, CEO and Founder, Rejuvenate Bio
03 Apr 2025
Contributed by Lukas
How do you turn back the epigenetic clock for humans and their animal companions? Host Chris O'Brien welcomes Dan Oliver, CEO and Founder of Rejuven...
Epsiode 50: Jonathan Rigby, Chairman and CEO, Sernova
18 Mar 2025
Contributed by Lukas
Now on the Few & Far Between podcast: Did you know that one in ten people with Type 1 Diabetes (TD1) die from hypoglycemia? Today's guest, who has...
Episode 49: Eileen Faucher, Principal and Founder, Brass Tacks Health
27 Feb 2025
Contributed by Lukas
Today on the Biorasi Few & Far Between podcast: What if you could read a story before its official release? Competitive intelligence gives you ear...
Episode 48: John Celebi, President and CEO, Sensei Bio
18 Feb 2025
Contributed by Lukas
"You have to have the right people, the right team, and good science." - John Celebi, President and CEO, Sensei Bio Welcome back to Biorasi's Few &...
Episode 46: Ben Olds and Amy Fenollosa, Haven Human Asset Ventures
15 Jan 2025
Contributed by Lukas
"There's that old saying, 'culture is how people behave when nobody's looking.' So, if you want to be effective, your [mission and value statements]...
Episode 47 - Marc Lajoie, CEO at Outpace Bio
31 Dec 2024
Contributed by Lukas
"If you bring powerful technology to a problem that is well understood, then you can really make a difference." - Marc Lajoie, CEO at Outpace Bio Wel...
Episode 46: Dr. Carsten Rudolph, CEO and Managing Director at Ethris
12 Dec 2024
Contributed by Lukas
"It's really a very important challenge we had from the very beginning, to see how to stabilize nanoparticles with the messenger RNA so they are not d...
Episode 44: Jonathan Scheiman, PhD, Co-Founder and CEO at FitBiomics
23 Oct 2024
Contributed by Lukas
"We don't endeavor to make elite athletes better. We endeavor to make society healthier." - Jonathan Scheiman, PhD, Co-Founder and CEO at FitBiomics ...
Episode 43: Isaac Stoner, Co-founder and CEO at Octagon Therapeutics
12 Sep 2024
Contributed by Lukas
"I hope we're moving into the age of the generalist, where knowing how to learn and learning how to learn are more important than specialized knowledg...
Episode 42: Diana Azzam, PhD, Assistant Professor at Florida International University, Co-Founder at First Ascent Biomedical
16 Jul 2024
Contributed by Lukas
“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I really ...
Episode 41: Craig Serra, Head of Clinical Research Scientific and Technical Engagement, Flatiron Health
23 May 2024
Contributed by Lukas
"It's amazing how many companies there are and how many opportunities for a kind of a match between a human that needs some help and a company that ca...
Episode 40: Professor Justin Stebbing, Editor-in-Chief, Oncogene journal
25 Apr 2024
Contributed by Lukas
"I learned very early on that the stupidest cancer cell was cleverer than the cleverest oncologist." - Justin Stebbing, Editor-in-Chief of Oncogene, p...
Episode 39: Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center
26 Mar 2024
Contributed by Lukas
"Technologies have changed enormously in terms of how we can basically procure, preserve, and then interrogate a tumor specimen...like effectively in ...
Episode 38: Dr. Ole Isacson, Professor of Neurology and Neuroscience, Harvard Medical School
22 Feb 2024
Contributed by Lukas
"Artificial Intelligence is a tool that really levels up and creates almost like an equity for everybody to participate and, when used effectively, to...
Episode 37: Will Greene, Prader-Willi Syndrome patient advocate, Healthcare Engagement Lead at Roche
24 Jan 2024
Contributed by Lukas
"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will Greene, Pr...
Episode 36: Zak Kohane, Department of Biomedical Informatics at Harvard Medical School
05 Dec 2023
Contributed by Lukas
"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware of the benef...
Episode 35: Charlene Son Rigby, CEO at Global Genes
14 Nov 2023
Contributed by Lukas
"And what I was really surprised about was that everybody was doing data collection in a different way. And I kept thinking that, gosh, there's a lot ...
Episode 34: Dan Mandell, CEO at GRO Biosciences
10 Oct 2023
Contributed by Lukas
"So we built the seatbelts before the car, so to speak, wherein we did a project to figure out ways to biocontain these organisms. And the strategy th...
Episode 33: Diana Sims-Silbermann, Clinician and Former Senior Trial Manager at Janssen Pharmaceuticals
20 Sep 2023
Contributed by Lukas
Episode 32: Stephanie Wisner, Author, Co-Founder at Centivax
17 Aug 2023
Contributed by Lukas
"In research or in biotech, time is expensive. Time is the most expensive thing that you have." - Stephanie Wisner, Author, Co-Founder at Centivax Bi...
Episode 31: Pam Cusick, SVP, Rare Patient Voice
20 Jun 2023
Contributed by Lukas
"What can I contribute that my doctor can't contribute? And that's a real 'a-ha' moment when we share with them how they're the experts in their condi...